Class 3 recall- Cyclizine Lactate 50 mg/ml Solution for injection

Orbit Pharma Limited is recalling a specific batch of Cyclizine Lactate 50 mg/ml Solution for injection as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies identified at the manufacturing site.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-orbit-pharma-limited-cyclizine-lactate-50-mg-slash-ml-solution-for-injection-el-26-a-slash-29?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5b8f7581-e919-44d3-a4fe-981a9bdc0779&utm_content=immediately

MHRA drug alert date: 16/06/26

Additional information:

For medical information enquiries and information on this product, please email customerservice@novumgen.com or telephone +44 203 096 6496. 

For stock control enquiries please email Stockcontrol@novumgen.com  

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Mirtazapine 30mg Tablets

Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery.

MHRA drug alert Date: 11/6/26

MHRA drug alert link: Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact pharmacovigilance-eu@cadilapharma.com or telephone +44 1217901596

For stock control enquiries please contact info@crescentpharma.com or telephone 01256 772730

Class 4 caution in use-Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe

Teva UK Limited is reporting a labelling error on the carton for Ponlimsi (Denosumab) 60mg Solution for injection in Pre-filled Syringe. The carton states “For application to the skin” when the product is licensed for subcutaneous use.

MHRA drug alert Date: 4/6/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email medinfo@tevauk.com

For stock control enquiries please email Customer.services@tevauk.com

Class 2 recall-ChloraPrep 2% 1mL and ChloraPrep Frepp 2% 1.5mL applicators

Becton Dickinson UK Ltd are recalling batches of ChloraPrep 2% 1mL applicators and ChloraPrep Frepp 2% 1.5 mL applicators due to a potential breach of sterility in the packaging process.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-becton-dickinson-uk-ltd-chloraprep-2-percent-1ml-and-chloraprep-frepp-2-percent-1-dot-5ml-applicators-el-26-a-slash-26?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=af065c4b-ae7c-4e93-b509-48708827dd95&utm_content=immediately

MHRA drug alert date: 02/06/26

Further Information

For all medical information enquiries and information on this product, please email safetyinformation@bd.com,  or telephone 08000437546.

For stock control enquiries please email info@insightbio.com,  or telephone 01707351330.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall- Ramipril caps 2.5mg

Crescent Pharma Limited is initiating a precautionary recall of one batch of Ramipril 2.5 mg Capsules following the identification of a potential packaging error at the manufacturing site.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-crescent-pharma-limited-ramipril-2-dot-5-mg-capsules-el-26-a-slash-25?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5c7ce4ea-d2a7-4959-9ebb-78481e349fed&utm_content=immediately#background

MHRA drug alert date: 28/05/26

Additional information:

For all medical information enquiries, please email medinfo@crescentpharma.com or telephone +44 1217901596.

For stock control enquiries please email complaints@crescentpharma.com.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Marion Shaw wins ‘Role Model of the Year’ at flagship Women in Data event

Marion Shaw, Senior Director of Data and Analytics at Alliance Healthcare, by Cencora, has been awarded ‘Role Model of the Year’ at Women in Data’s Flagship event in London. The award was presented by Roisin McCarthy, Founder of Women in Data, recognising Marion’s leadership, expertise and commitment to supporting others in the field of data and analytics. The honour also reflects her ongoing contribution to innovation, excellence and the development of more inclusive teams within the sector.

The event was attended by leaders, peers and professionals from across the data and analytics industry. Marion was joined by colleagues and her daughter, making the recognition especially meaningful.

Marie Evans, Managing Director of Alliance Healthcare, By Cencora, said:“This award is testament to Marion’s leadership and vision. It’s fantastic to see Marion recognised as an expert in her field and as someone who continues to inspire others.”

Women in Data is a not-for-profit organisation dedicated to promoting greater representation and equality across data and analytics. Women remain significantly under-represented across STEM fields, with male analysts and data scientists outnumbering their female colleagues by four to one across the industry. Greater diversity in data is vital, helping to ensure that insight, analysis and decision-making are stronger, more responsible and more reflective of the people and communities they serve.

Commenting on her win, Marion Shaw said:“Women in Data is so much more than just an organisation. It’s a family where support and encouragement are given freely, and where learning, growth, mentoring and being mentored happen naturally. Having been part of this group since its early days, I have been truly inspired by the way it has grown into a vibrant collective of role models.”

Marion’s recognition is a proud moment and a reflection of the important role she plays in championing data, analytics and inclusive leadership.

Congratulations Marion!

*Source: Women in Data®

Class 4 caution in use-balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis

Fresenius Medical Care Deutschland GmbH have identified an error in the Braille printed on the outer label. The Braille message on the balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, incorrectly states ‘CAPD/DPCA 19’. All other label information and printed data are correct for all above listed batches.

MHRA drug alert Date: 14/5/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Fresenius Medical Care Deutschland GmbH, balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, EL(26)A/24 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email Medinfo-UK@freseniusmedicalcare.com, or telephone 01623 445 215. For stock control enquiries please email ukorders@freseniusmedicalcare.com, or telephone 01623 445 100.

Class 4 caution in use-Loperamide hydrochloride 2 mg Orodispersible Tablets

Milpharm Limited has identified a discrepancy in the Patient Information Leaflet (PIL) approved for Loperamide hydrochloride 2 mg Orodispersible Tablets.

MHRA drug alert Date: 11/5/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email medinfo@aurobindo.com, or telephone 020 8845 8811.

For stock control enquiries please email customerservices.uk@aurobindo.com, or telephone 020 8845 8811.

Alphega Pharmacy member success at the Scottish Pharmacy Awards

Alliance Healthcare UK, by Cencora proudly sponsored the Scottish Pharmacy Awards, Customer Award - championing collaboration and progress across the pharmacy sector. 

The awards celebrate excellence, leadership and innovation across community pharmacy in Scotland, and Alphega Pharmacy is extremely proud to see its members acknowledged for their outstanding contribution to patient care and pharmacy services.  

Congratulations to the award winners:  

• Pharmacist of the Year – Glenn Davie, Barnton Pharmacy and Travel Clinic, Edinburgh  
• Community Pharmacy Service Award – Lesley-Anne Graham, Lindsay & Gilmour, West Calder Health Centre  

This recognition reflects the hard work, dedication and professionalism shown by Alphega members every day in serving their local communities. Achievements like these highlight the vital role community pharmacy continues to play across Scotland.  

Congratulations to both winners on this well‑deserved success and to all nominees. 

Class 2 recall-Sertraline 100mg tablets

Amarox Limited is recalling one batch of Sertraline 100 mg film-coated tablets as a precautionary measure due to an error at the manufacturing site.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-amarox-limited-sertraline-100mg-film-coated-tablets-el-26-a-slash-22?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2339f367-dda6-4275-90fc-0e7281517b0d&utm_content=immediately

MHRA drug alert date: 28/04/26

Further Information

For all medical information enquiries, information and for reporting of side effects please email Safety@Amaroxpharma.com or telephone +44 2039720005 and for stock control enquiries please email info@amaroxpharma.com or telephone +44 2039720002.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.